Psychedelic Medicine

Through the late 1960’s, certain psychedelic treatments were legal. In the 1970’s, 

as a response to the stigmatization of recreational use, psychedelics became 

classified as a Schedule I narcotic and were therefore illegal.

Despite the fact that psychedelics are illegal, the last decade has seen an explosion of  research showing clinical benefits,

with results so intriguing that governments  are greenlighting

studies and  approvals around the world.

As a result of the increase in research from non-commercial entities to revisit

psychedelic use for mental health, psychedelic assisted therapies

were granted “Break Through” status by the FDA in 2018.

Pile of Pills

With the change in status, there has been a

renaissance of research 

into the role of LSD,

psilocybin (aka “magic mushrooms”),

MDMA (aka “ecstasy”), DMT (aka “ ayahuasca ”),

ketamine and other psychedelic substances

in treating

depression, PTSD, addiction,

and other forms of mental illness.


There is a growing interest 

in bringing the potential benefits

of these compounds to

many individuals.

These benefits can

help individuals

attain more aspirational

levels of well being.

The psychedelic medicine market has continued to be explored through
multiple research studies. According to, in the US the
number of active studies for psychedelics include:   

                 56                     90                    115                      10
                  Psilocybin Studies                 MDMA studies                        LSD studies                             DMT studies